Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in new hampshire and vermont

Abstract

The authors identified all newly diagnosed lung cancer cases in New Hampshire and Vermont for the period 1973 through 1976 and abstracted clinical data on presenting symptoms and findings from their hospital records. Microscopy slides were also reviewed, when possible, to confirm cell type. The most frequent presenting symptoms were weight loss (46%) and cough (45%). Other common symptoms were dyspnea (37%), weakness (34%), chest pain (27%), and hemoptysis (27%). The presence of symptoms and findings was in general related to disease stage but bore little relationship to cell type. These results differ from those of previously reported case series that were based on surgical, radiation therapy, or Veterans Hospital groups, but the current data agree closely with those from another population-based series in Finland.

Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology

“…Chute et al did not find any relationship between presence of pain and underlying histological subtype [22].…”

“…Two studies did not find any relationship between the presence of pain and stage of disease [9,22]. However, Chute et al found that whilst chest pain did not predict disease stage, the presence of pain elsewhere at presentation doubled the likelihood that a patient had stage III disease [22].…”

Żywienie drogą przewodu pokarmowego (żywienie dojelitowe)

“…Co ważne, nie ma żadnych wiarygodnych danych wskazujących na to, że leczenie żywieniowe ma wpływ na pobudzanie wzrostu nowotworu, czyli przyspieszenie rozwoju choroby, chociaż nie można wykluczyć stymulującego wpływu niektórych składników odżywczych na wzrost nowotworu [2]. Z kolei niedobór składników odżywczych w sposób oczywisty nie tylko nie hamuje rozwoju nowotworu, ale także istotnie pogarsza stan chorego, zmniejsza tolerancję leczenia onkologicznego, zwiększa ryzyko wystąpienia powikłań i może prowadzić do przerwania leczenia przeciwnowotworowego, a w skrajnych przypadkach nawet do zgonu [5][6][7][8][9]. Niedożywienie jest także niezależnym negatywnym czynnikiem prognostycznym i zwiększa ryzyko wystąpienia toksyczności leczenia przyczynowego [10][11][12].…”

Prognostic Significance of (18) F-Fluorodeoxyglucose - Positron Emission Tomography After Treatment in Patients With Limited Stage Small Cell Lung Cancer

“…In 2008, the American Cancer Society estimates 208,657 new cases of lung cancer will be diagnosed and 161,775 will die of the disease. 1,2 Small cell lung cancer (SCLC) represents 15% to 25% of all lung cancers and occurs almost exclusively in smokers. At presentation 30% to 40% of patients with SCLC have limited stage disease, i.e.…”

“…[1][2][3] Overall response rates of up to 85% can be achieved in newly diagnosed patients with limited stage SCLC treated with a multiple drug regimen and concurrent radiation therapy, with a complete response in 40% to 60%. 2,4,5 Median survival for limited stage SCLC is approximately 15 to 20 months with a 5-year survival rate of 10% to 13%. 4,6,7 Unfortunately, the majority of patients develop recurrent cancer.…”